Methoxyamine combinations in the treatment of cancer
AssigneeCase Western Reserve University
InventorsStanton L. Gerson, Lili Liu
Life of this patent
Estimating the term…
Abstract
This invention generally relates to novel compositions and methods for the treatment of certain cancers. Additionally, this invention relates to novel compositions and methods to screen drugs for the treatment of certain cancers. Specifically, the invention contemplates that temozolomide and methoxyamine, in combination or in sequence, shall be used as a treatment for certain tumors that are resistant to treatment by temozolomide alone. Additionally, methoxyamine is contemplated for methods of treatment of cancer, wherein methoxyamine is used, in combination or in sequence, with other anticancer drugs or agents.
Claims19
A method comprising:
- a) providing i) a patient diagnosed with cancer, ii) a first formulation comprising methoxyamine and iii) a second formulation comprising 1,3-bis(chloroethyl) 2-nitrosourea (BCNU);
- b) administering said first formulation to said patient;
- and
- c) administering said second formulation to said patient;
- wherein said methoxyamine is administered in an amount sufficient to potentiate toxicity of said BCNU.
A formulation comprising methoxyamine and BCNU.
A method comprising:
- a) providing i) a patient diagnosed with cancer, ii) a first formulation comprising methoxyamine and iii) a second formulation comprising an anticancer drug or agent that exerts cytotoxicity mediated by oxidative DNA damage;
- b) administering said first formulation to said patient;
- and
- c) administering said second formulation to said patient;
- wherein said methoxyamine is administered in an amount sufficient to potentiate toxicity of said anticancer agent or drug.
A method comprising:
- a) providing i) a patient diagnosed with cancer, ii) a first formulation comprising methoxyamine and iii) a second formulation comprising an anticancer drug or agent selected from the group consisting of hypoxanthine, 5-FU, uracil, IUdR, bleomycin and adriamycin;
- b) administering said first formulation to said patient;
- and
- c) administering said second formulation to said patient;
- wherein said methoxyamine is administered in an amount sufficient to potentiate toxicity of said anticancer drug or agent.
A formulation comprising methoxyamine and an anticancer drug or agent selected from the group consisting of hypoxanthine, 5-FU, uracil, IUdR, bleomycin and adriamycin.
A method comprising:
- a) providing i) a patient diagnosed with cancer, ii) a first formulation comprising methoxyamine and iii) a second formulation comprising iododeoxyuridine (IUdR);
- b) administering said first formulation to said patient;
- and
- c) administering said second formulation to said patient;
- wherein said methoxyamine is administered in an amount sufficient to further increase the radiosensitivity of the tumor cells in said patient.
Dependencies are inferred from the claim text.